Online citations, reference lists, and bibliographies.
Referencing for people who value simplicity, privacy, and speed.
Get Citationsy
← Back to Search

CD4+ Helper T Cells Are Required For Resistance To A Highly Metastatic Murine Tumor

H. Schild, B. Kyewski, P. von Hoegen, V. Schirrmacher
Published 1987 · Biology, Medicine

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Share
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
A role of CD4+ T helper cells in induction of tumor transplant rejection leading to complete regression of a highly metastatic DBA/2 mouse lymphoma was analyzed. Using an anti‐CD4 monoclonal antibody (GK1.5) which eliminates T helper cells in vivo and in vitro, we found that CD4+ cells are required for tumor resistance in syngeneic DBA/2 mice or allogeneic but major histocompatibility complex‐identical B10.D2 mice. In contrast, in allogeneic C57BL/6 mice tumor rejection was independent of CD4+ cells. An analogous requirement for immune CD4+ cells for in vitro induction of CD8+ tumor‐specific cytotoxic T cells was found in these respective strains. The requirement for immune CD4+ cells in vitro could be replaced by recombinant interleukin 2. These results demonstrate a role of CD4+ regulatory T cells and T‐T cell cooperation in the induction of anti‐tumor immunity and tumor rejection, and point to possible therapeutic interventions in the afferent phase of anti‐tumor immune responses.
This paper references
10.1146/ANNUREV.IY.04.040186.003341
Cancer Immunotherapy Using Interleukin-2 and Interleukin-2-Activated Lymphocytes
S. Rosenberg (1986)
10.1084/JEM.161.2.378
Successful treatment of autoimmunity in NZB/NZW F1 mice with monoclonal antibody to L3T4
D. Wofsy (1985)
10.1002/1097-0142(19850315)55:6<1236::AID-CNCR2820550616>3.0.CO;2-#
Prospectively randomized trial of adjuvant active‐specific immunotherapy for human colorectal cancer
H. C. Hoover (1985)
T-cell immunity to murine Moloney sarcoma virus-induced tumours: L3T4+ T cells are necessary for resistance to primary sarcoma growth, but Lyt-2+ T cells are required for resistance to secondary tumour cell challenge.
W. Bateman (1987)
10.1084/JEM.163.3.603
Characterization of two distinct primary T cell populations that secrete interleukin 2 upon recognition of class I or class II major histocompatibility antigens
T. Mizuochi (1986)
10.1126/SCIENCE.3155574
Reversal of experimental allergic encephalomyelitis with monoclonal antibody to a T-cell subset marker.
M. Waldor (1985)
10.1111/j.1600-065X.1979.tb00289.x
Xenogeneic Monoclonal Antibodies to Mouse Lymphoid Differentiation Antigens *
J. Ledbetter (1979)
Immunogenetic studies on the resistance of mice to highly metastatic DBA/2 tumor cell variants. I. Effect of incompatibilities at H-2 or non-H-2 genes in normal and nude (nu/nu) mice.
V. Schirrmacher (1981)
Inhibition of humoral immunity in vivo by monoclonal antibody to L3T4: studies with soluble antigens in intact mice.
D. Wofsy (1985)
10.1038/314098A0
Expression of interleukin-2 receptors as a differentiation marker on intrathymic stem cells
R. Ceredig (1985)
10.1101/SQB.1977.041.01.068
Regulatory mechanisms in the immune response to cell-surface antigens.
P. Lake (1977)
10.1038/322541a0
Capacity of purified Lyt-2+ T cells to mount primary proliferative and cytotoxic responses to Ia− tumour cells
J. Sprent (1986)
10.1002/IJC.2910240114
Tumor metastases and cell‐mediated immunity in a model system in DBA/2 mice. V. Transfer of protective immunity with H‐2 identical immune T cells from B10.D2 mice
V. Schirrmacher (1979)
Immunogenetic studies on the resistance of mice to highly metastatic DBA/2 tumor cell variants. II. Influence of minor histocompatibility antigens on tumor resistance, gamma-interferon induction and cytotoxic response.
V. Schirrmacher (1981)
10.1073/PNAS.82.13.4495
Influence of dendritic cells on tumor growth.
S. Knight (1985)
10.1084/JEM.164.3.911
Long-term humoral unresponsiveness in vivo, induced by treatment with monoclonal antibody against L3T4
J. Goronzy (1986)
IgG or IgM monoclonal antibodies reactive with different determinants on the molecular complex bearing Lyt 2 antigen block T cell-mediated cytolysis in the absence of complement.
M. Sarmiento (1980)
10.1038/312548A0
Therapy with monoclonal antibodies by elimination of T-cell subsets in vivo
S. Cobbold (1984)
10.1016/0167-5699(84)90233-0
High determinant density may explain the phenomenon of alloreactivity.
M. Bevan (1984)
10.1002/IJC.2910230216
Tumor metastases and cell‐mediated immunity in a model system in DBA/2 mice.: Iv. Antigenic differences between a metastasizing variant and the parental tumor line revealed by cytotoxic T lymphocytes
V. Schirrmacher (1979)
10.1016/S0065-230X(08)60024-X
Human cancer-associated antigens: present status and implications for immunodiagnosis.
D. Sulitzeanu (1985)
10.1002/IJC.2910230215
Tumor metastases and cell‐mediated immunity in a model system in DBA/2 mice. I. Tumor invasiveness in vitro and metastasis formation in vivo
V. Schirrmacher (1979)
10.1111/1523-1747.EP12519909
Surface densities of Langerhans cells in relation to rodent epidermal sites with special immunologic properties.
P. Bergstresser (1980)
10.1016/0008-8749(87)90317-0
New antigens presented on tumor cells can cause immune rejection without influencing the frequency of tumor-specific cytolytic T cells.
P. von Hoegen (1987)
10.1126/SCIENCE.2955518
Islet allograft survival after a single course of treatment of recipient with antibody to L3T4.
J. Shizuru (1987)
10.1038/328077A0
Induction of cytotoxic T-cell responses in vivo in the absence of CD4 helper cells
R. Mark L. Buller (1987)
Characterization of the murine T cell surface molecule, designated L3T4, identified by monoclonal antibody GK1.5: similarity of L3T4 to the human Leu-3/T4 molecule.
D. Dialynas (1983)
10.1084/JEM.162.3.1105
Prevention of type II collagen-induced arthritis by in vivo treatment with anti-L3T4
G. Ranges (1985)



This paper is referenced by
10.1084/JEM.189.5.753
CD4 T Cells and Their Role in Antitumor Immune Responses
R. Toes (1999)
10.4049/jimmunol.169.1.350
Established Human Papillomavirus Type 16-Expressing Tumors Are Effectively Eradicated Following Vaccination with Long Peptides1
S. Zwaveling (2002)
10.1007/BF01742538
Potentiation of the efficacy of murine L1210 leukemia vaccine by a novel immunostimulator 7-thia-8-oxoguanosine: Increased survival after immunization with vaccine plus 7-thia-8-oxoguanosine
B. S. Sharma (2005)
10.1002/IJC.2910430225
Recruitment and activation of tumor‐specific immune t cells in situ: Functional studies using a sponge matrix model
U. Zangemeister (1989)
10.3892/ol.2017.6473
A cytokine signal inhibitor for rheumatoid arthritis enhances cancer metastasis via depletion of NK cells in an experimental lung metastasis mouse model of colon cancer.
Hideki Shimaoka (2017)
10.1016/S0008-8749(03)00062-5
A novel tumour model system for the study of long-term protective immunity and immune T cell memory.
Y. Mahnke (2003)
10.1007/BF01756594
In situ activation of syngeneic tumour-specific cytotoxic T lymphocytes: Intra-pinna immunization followed by restimulation in the peritoneal cavity
V. Schirrmacher (2005)
10.1007/s00262-008-0525-2
A novel CD4 T-cell epitope described from one of the cervical cancer patients vaccinated with HPV 16 or 18 E7-pulsed dendritic cells
X. Wang (2008)
10.1084/JEM.174.5.957
Anti-CD2 antibodies induce T cell unresponsiveness in vivo
B. Gueckel (1991)
10.1111/j.1600-065X.1999.tb01331.x
Human tumor antigens for cancer vaccine development
R. Wang (1999)
10.1016/0008-8749(91)90069-N
Effector phenotypes and mechanisms of antitumor immune reactivity of tumor-immunized and tumor-bearing mice in two syngeneic tumors.
S. Fuyama (1991)
10.1038/sj.gt.3301220
Intra-pinna anti-tumor vaccination with self-replicating infectious RNA or with DNA encoding a model tumor antigen and a cytokine
V. Schirrmacher (2000)
10.1615/CRITREVIMMUNOL.V20.I6.10
Autoimmunity and the immunotherapy of cancer: targeting the "self" to destroy the "other".
W. Overwijk (2000)
10.1007/978-3-642-79553-4_5
Grundlagen immunologischer Vorgänge beim Plattenepithelkarzinom im Kopf-Hals-Bereich — Diagnostik und Ursachen
T. P. Wustrow (1995)
10.1097/PPO.0b013e3181eacba8
Adoptive Therapy Using Antigen-Specific T-Cell Clones
C. Yee (2010)
10.1006/SCBI.2001.0384
T-cell immunity in the induction and maintenance of a tumour dormant state.
V. Schirrmacher (2001)
10.1179/ISR.1989.14.3.291
Immunobiology and Immunotherapy of Cancer Metastases Ten-Year Studies in an Animal Model Resulting the Design of an Immunotherapy Procedure now under Clinical Testing
V. Schirrmacher (1989)
10.5772/24449
The Beneficial Effects of Nutritional Compounds on Breast Cancer Metastasis
Jeffrey D. Altenburg (2011)
10.4049/jimmunol.172.7.4215
CD4-Directed Peptide Vaccination Augments an Antitumor Response, but Efficacy Is Limited by the Number of CD8+ T Cell Precursors1
H. Hanson (2004)
10.1002/ijc.10518
Renal cell carcinoma–associated antigen G250 encodes a naturally processed epitope presented by human leukocyte antigen‐dr molecules to CD4+ T lymphocytes
J. Vissers (2002)
10.1002/ijc.25238
In vivo tumor suppression activity by T cell‐specific T‐bet restoration
Kihyun Lee (2010)
10.1007/0-387-27545-2_4
Tumor antigens and tumor antigen discovery.
D. Graziano (2005)
Induction of p53-specific immune responses in colorectal cancer patients receiving a recombinant ALVAC-p53 candidate vaccine.
S. H. van der Burg (2002)
10.1128/IAI.69.2.1032-1043.2001
Immunomodulatory Effects of Anti-CD4 Antibody in Host Resistance against Infections and Tumors in Human CD4 Transgenic Mice
D. Herzyk (2001)
10.4049/jimmunol.165.10.5451
Tumor Cells Present MHC Class II-Restricted Nuclear and Mitochondrial Antigens and Are the Predominant Antigen Presenting Cells In Vivo1
L. Qi (2000)
10.1007/BF00210630
New insights into tumor-host interactions in lymphoma metastasis
V. Umansky (2004)
10.1007/BF01741332
Specific eradication of micrometastases by transfer of tumour-immune T cells from major-histocompatibility-complex congenic mice
V. Schirrmacher (2005)
10.4049/jimmunol.172.11.6598
Activation-Induced Cell Death Limits Effector Function of CD4 Tumor-Specific T Cells1
R. Saff (2004)
10.1007/BF02221324
Transfer of long-lasting tumor immunity by immune T cells from MHC congenic mice: Migration, survival and tumor-protectivity of cytotoxic donor cells
U. Zangemeister-Wittke (1991)
10.1007/978-1-4615-2013-9_16
Cellular adoptive immunotherapy after bone marrow transplantation.
S. Riddell (1995)
10.1007/BF00205796
Modification of tumor cells by a low dose of Newcastle disease virus
H. Schild (2004)
A novel model system for the study of anti-tumour T-cell memory
Y. Mahnke (2001)
See more
Semantic Scholar Logo Some data provided by SemanticScholar